SCHEMBL5541330

SCHEMBL5541330

[CH2]c1cnc(-c2cccc(F)c2)o1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.47
GRM5 P41594 1/20 0.42
TP53 P04637 1/20 0.42
HPN P05981 1/20 0.42
MAOB P27338 2/20 0.40
IDO1 P14902 2/20 0.40
HSD17B1 P14061 1/20 0.40
HSD17B2 P37059 1/20 0.40
PTK2 Q05397 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HPGDS O60760 3/20 0.38
TAAR1 Q96RJ0 1/20 0.38
ESR2 Q92731 1/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
NR4A1 P22736 1/20 0.37
NR4A2 P43354 1/20 0.37
NR4A3 Q92570 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541340 0.79 MET (0.53) NOTUMGRM5TP53HPNMAOB
SCHEMBL5543168 0.78 RAB9A (0.52) NOTUMTP53MAOBACHE
SCHEMBL5543233 0.77 ALOX15 (0.59) NOTUMTP53
SCHEMBL31341107 0.74 NR4A1 (0.61) NOTUMHPNHPGDSNR4A1NR4A2
SCHEMBL31341164 0.73 HPGDS (0.52) NOTUMTP53HPNHPGDSNR4A1
SCHEMBL5539633 0.70 MAOB (0.48) NOTUMGRM5TP53HPNMAOB
SCHEMBL5543447 0.70 SLC9A1 (0.48) NOTUMGRM5TP53HPNMAOB
SCHEMBL3619213 0.70 NOTUM (0.49) NOTUMTP53MAOBPTK2
SCHEMBL12171399 0.69 VCP (0.52) TP53HSD17B1HSD17B2L3MBTL1HPGDS
SCHEMBL5545318 0.69 NR4A1 (0.56) NOTUMTAAR1ESR2NR4A1NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-102532162-A 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2012-07-04 CN disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NOTUM 3827/4885GRM5 897/4885TP53 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.